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ABSTRACT: Inhibition of the major cyclic adenosine mono-
phosphate-metabolizing enzyme PDE4 has shown potential for the
discovery of drugs for cancer, inflammation, and neurodegenerative
disorders such as Alzheimer’s disease. As a springboard to explore
new anti-cancer and anti-Alzheimer’s chemical prototypes from
rare Annonaceae species, the present study evaluated anti-PDE4B
along with antiproliferative and anti-cholinesterase activities of the
extracts of the Philippine endemic species Uvaria alba using in vitro
assays and framed the resulting biological significance through
computational binding and reactivity-based experiments. Thus, the
PDE4 B2B-inhibiting dichloromethane sub-extract (UaD) of U.
alba elicited antiproliferative activity against chronic myelogenous
leukemia (K-562) and cytostatic effects against human cervical
cancer (HeLa). The extract also profoundly inhibited acetylcholinesterase (AChE), an enzyme involved in the progression of
neurodegenerative diseases. Chemical profiling analysis of the bioactive extract identified 18 putative secondary metabolites.
Molecular docking and molecular dynamics simulations showed strong free energy binding mechanisms and dynamic stability at 50-
ns simulations in the catalytic domains of PDE4 B2B, ubiquitin-specific peptidase 14, and Kelch-like ECH-associated protein 1
(KEAP-1 Kelch domain) for the benzylated dihydroflavone dichamanetin (16), and of an AChE and KEAP-1 BTB domain for 3-
(3,4-dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-dimethoxychalcone (8) and grandifloracin (15), respectively. Density functional theory
calculations to demonstrate Michael addition reaction of the most electrophilic metabolite and kinetically stable grandifloracin (15)
with Cys151 of the KEAP-1 BTB domain illustrated favorable formation of a β-addition adduct. The top-ranked compounds also
conferred favorable in silico pharmacokinetic properties.
1. INTRODUCTION
The cell cycle is tightly regulated by cyclic nucleotide signaling
ascribed as a composite component of tumor pathogenesis.
Impairments in the synthesis of cyclic adenosine mono-
phosphate (cAMP) or cyclic guanosine monophosphate by
regulating phosphodiesterase enzymes (PDEs) have been
linked to cancer pathologies.1,2 Thus, the cellular regulation
of cAMP signaling has been an attractive target in designing
small molecules for a wide array of diseases, including cancer
and Alzheimer’s.3,4 Among the 11 PDE enzyme families, PDE4
specifically catalyzes the hydrolysis of cAMP.1,2,5 Tumor cells
originating from the central nervous system, lung, blood, and
breast have an upregulated PDE4 level that primarily drives
cAMP hydrolysis.5 Thus, PDE4 is an attractive target for
cancer chemotherapy. PDE4 inhibitors suppress tumor growth
and induce apoptosis in cancer cells.6 The ubiquitin-
proteasome pathway is another potential drug target for
carcinogenesis involved in synchronized proteolysis of cyclins
and cyclin-dependent kinase inhibitors critical for cell cycle
progression.7,8 Protein ubiquitination is primarily regulated by
deubiquitinases (DUBs). Thus, inhibiting DUBs, such as
ubiquitin-specific peptidase 14 (USP14), may induce apoptosis
in cancer cells while conferring low cytotoxicity to normal
cells.8 The cytoprotective mechanism of the body against
oxidative stress involving the Kelch-like ECH-associated
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protein 1 (KEAP-1)−nuclear factor erythroid 2 (Nrf2)−
antioxidant response element pathway is another related
interesting avenue for cancer therapy.9 Oxidative stress is the
underlying contributor to virtually every chronic disease. Thus,
disrupting the KEAP-1−Nrf2−ARE (antioxidant response
element) pathway and consequently enhancing Nrf2 activity
are promising strategies for preventing chronic diseases
involving oxidative stress and inflammation.10 Natural
products, particularly those with unsaturated electrophilic
moieties, have been identified to target USP14 and KEAP-
1.9,11
Meanwhile, there have been studies indicating that selective
inhibition of PDE4 may potentially treat neurodegenerative
disorders, including Alzheimer’s disease (AD).12 Similarly,
inhibition of acetylcholinesterase enzyme (AChE) represents a
therapeutic strategy for managing AD. AChE catalyzes the
hydrolysis of acetylcholine that is vital in memory formation
and cognitive functions.13 Several pre-clinical studies indicate
that PDE4 and AChE inhibitors mitigate deficits in long-term
memory caused by oxidative stress, aging, and overexpression
of amyloid-β plaques and neurofibrillary tangles in brain
tissues. Thus, PDE4 and AChE inhibitors hold promise in the
treatment of neurodegenerative and inflammatory diseases.14
The genus Uvaria Linn. (family Annonaceae) is a prolific
source of pharmacologically active natural products exhibiting
biological activities such anti-cancer, anti-inflammatory,
antitubercular, antioxidant, and antimicrobial activities.15−22
Despite numerous studies on several Uvaria species, limited
scientific efforts have been described for the endemic
Philippine medicinal plant, Uvaria alba. Thus, our present
investigation focused on the in vitro evaluation of the anti-
phosphodiesterase, antiproliferative, and anti-cholinesterase
activities of the dichloromethane (DCM) sub-extract of U.
alba along with computational-driven drug discovery experi-
ments to identify specific inhibitors that could target USP14,
KEAP-1 domains [Tramtrack and Bric-a-̀Brac (BTB) and
Kelch], PDE4 B2B, and AChE enzymes. A density functional
theory (DFT) calculation was also performed to model a
possible Michael addition reaction of electrophilic metabolites
with KEAP1 and illustrate irreversible, covalent inhibitions.
2. RESULTS AND DISCUSSION
2.1. Anti-phosphodiesterase, Antiproliferative, and
Anti-cholinesterase Profiles of U. alba Extracts. The
phosphodiesterase inhibitory activities of the U. alba extracts
were assessed against human recombinant cAMP-specific
phosphodiesterase (PDE4 B2). The U. alba crude extract
was shown to inhibit PDE4 B2 in comparison with the
standard drug rolipram (IC50 = 0.22 μg/mL). Among the sub-
extracts, the DCM extract exhibited inhibition against PDE4





test sample anti-PDE4 B2 IC50
e (μg/mL) HUVECh K-562i HeLaj anti-AChE IC50
e (μg/mL)
Ua crudea >20 >50 >50 cytostatic 0.25 + 0.03
UaBb >20 >50 >50 >50 0.24 + 0.01
UaPc >20 21.3 + 0.7 16.7 + 1.6 cytostatic 0.25 + 0.02
UaDd 16.8 + 3.89 24.1 + 1.6 12.3 + 1.8 cytostatic 0.22 + 0.01
doxorubicin 0.1 + 0.5 1.0 + 0.6 2.0 ± 0.8
rolipram 0.22 + 0.10
galantamine 0.14 + 0.01
aCrude DCM−methanol (1:1) extract. bPetroleum ether sub-extract. cPetroleum ether sub-extract. dDCM sub-extract. eInhibitory
concentration50. fGrowth inhibition50. gCytotoxic concentration50 hHuman umbilical vein endothelial cells. iChronic myelogenous
leukemia cells. jCervical cancer cells.
Figure 1. Cytostatic curve of the crude Ua extract, DCM (UaD), and petroleum ether (UaP) sub-extracts against HeLa.
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B2 with an IC50 of 16.8 μg/mL (Table 1). The role of
phosphodiesterases (PDEs) in carcinogenesis has been
established in several studies. PDE4 B2 participates in signal
transduction by regulating cellular concentrations of cyclic
nucleotides2 and is upregulated in colorectal cancer with
oncogenic KRAS, thereby inhibiting apoptosis and disrupting
cell polarity.23 In addition, PDE4 inhibitors may also induce
apoptosis in chronic lymphocytic leukemia by activating PP2A-
induced dephosphorylation of proapoptotic Bcl-2.24
To further evaluate the role of U. alba constituents in
carcinogenesis, the extracts were assessed for anti-proliferative
and cytotoxic activities using the CellTiter-Blue assay (Table 1,
Figure 1). The DCM (UaD) and petroleum ether (UaP) sub-
extracts were shown to be antiproliferative against chronic
human myelogenous leukemia cells (K-562). Interestingly, the
crude extract Ua as well as the sub-extracts UaD and UaP
elicited cytostatic effects against HeLa. An extract or plant
component is cytostatic if it inhibits cell proliferation over a
large range of concentrations compared to a reference drug.
The downregulation of PDE4 B2 has also been implicated
with neuronal plasticity and pro-cognitive development; thus,
the PDE4 B2 inhibitory property UaD sub-extract may also
confer neuroprotective effects. This claim is further strength-
ened when UaD inhibited AChEan enzyme responsible for
terminating nerve impulse transmission at the cholinergic
synapses by rapid hydrolysis of acetylcholine. A strong AChE
inhibition (IC50 = 0.22 μg/mL) was observed in comparison
with the positive drug standard galantamine (IC50 = 0.14 μg/
mL). Similar to PDE4 B2, inhibition of AChE is also
recognized as a strategy for treating Alzheimer’s and
Parkinson’s diseases.13 Thus, UaD may exhibit neuroprotective
effects by modulating the activity of both PDE4 B2 and AChE.
2.2. HPLC-MS-Quantitative Time-of-Flight Profiling of
the UaD Sub-Extract. The UaD sub-extract was chemically
profiled to putatively identify secondary metabolites present
using LC-HR-ESIMS-quantitative time-of-flight (QToF) anal-
ysis (Figures S1 and S2). Eighteen compounds, namely, 7-
benzoyloxy-2H-1-benzopyran-2-one (1), uvaridapoxide A (2),
Figure 2. Secondary metabolites 1−18 detected in the DCM sub-extract of U. alba.
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microcarpin A (3), microcarpin B (4), grandiuvarone (5),
uvaridacane A (6), valderramenol A (7), 3-(3,4-dihydrox-
ybenzyl)-3′,4′,6-trihydroxy-2,4-dimethoxychalcone (8), alba-
nol A (9), tepanone (10), valderramenol B (11), 5-O-
methylchamanetin (12), cyathosthemine (13), bractelactone
(14), grandifloracin (15), dichamanetin (16), albanol B (17),
and cyathoviridine (18) were identified (Figure 2, Table S1).
These compounds have been previously identified from Uvaria
and other related genera of Annonaceae and are known to
confer cytotoxic and/or anti-inflammatory properties.
2.3. Molecular Docking to PDE4B2. The structure of
PDEs comprises three domains, with the catalytic domain
being the most conserved among the PDE isoenzymes. PDE4
B2B, in particular, comprises an N-terminal regulatory domain
(residues 1−151), a catalytic domain (residues 152−489), and
a C-terminal domain (residues 490−568). To assess the
binding characteristics of 1−18, a molecular docking approach
was performed against PDE4 B2B, directed to the binding
domain of the enzyme. Dichamanetin (16) and grandifloracin
(15) displayed the highest binding affinity with a binding
energy (BE) of −10.2 kcal/mol each (Table 2). Compound
16’s attachment to the binding domain of the enzyme is mostly
due to pi−pi interplay occurring in four regions of the
molecule: the chromanone core against Met347; a phenyl
substituent against Phe414 and Phe446; 8-hydroxybenzyl
against Tyr233 and Tyr410; and 6-hydroxyphenyl with
Leu303. A hydrogen bonding was also observed between
Asp392 and a hydroxyl substituent of the chromanone core.
Grandifloracin (15) was strongly bound to the active site of
the enzyme through intramolecular conventional hydrogen
bonds with (a) a hydroxyl substituent against His234 and (b)
the electronegative oxygens of two ester groups against
Tyr233, His278, and Asn283. Another notable compound
that conferred strong binding affinity against PDE4 B2B is
bractelactone (14) with a BE of −10.1 kcal/mol (Table 2,
Figure 3). Bractelactone’s (14) attachment to putative binding
was markedly strengthened by hydrogen bonding between two
hydroxyl substituents of the benzofuranone core against
His238, His274, Tyr233, and Asp392. For compound 14, a
pi−anion and a pi−sulfur intermolecular attraction was
observed between Glu304 against the compound’s xanthone
core and Cys432 against a benzoyl substituent. Of the three
top-scoring ligands, bractelactone (14) was further subjected
to molecular dynamics (MD) simulations because it showed a
better ADMETox profile.
2.4. Molecular Docking to Cancer Targets USP14 and
KEAP-1 (Kelch and BTB Domains). USP14, a member of
the deubiquitinating enzymes, is an important potential drug
target due to its involvement in cancer development and
neurodegenerative diseases. Regulation of the ubiquitin-
proteasome system is an essential control mechanism and
potential inhibitor of DUBs, including USP14 and thus, may
balance and prevent disruption of this regulatory system. The
benzylated hydroxyflavones, dichamanetin (16) and 5-O-
methylchamanetin (12), exhibited favorable binding to the
putative binding domains of USP14 with BEs of −9.8 and −9.4
kcal/mol, respectively (Table 2, Figure 3). The chromanone
core of 16 is affixed to the binding pocket through pi−anion
interaction against Asp199 and stacked pi−amide bonding
with Gln198. The hydroxybenzyl moiety is also bound through
pi−alkyl and stacked pi−pi attraction with Tyr476, Lys342,
and Arg330. There are two prominent stacked pi−pi
interactions responsible for compound 12’s attachment to
the binding site: (a) Phe331 with the phenyl ring B of the
hydroflavone moiety and (b) Tyr476 and the benzyl group.
Molecular docking was also performed for KEAP-1, a
member of the BTB-Kelch family of proteins known to interact
with Nrf2.25,26 Activation with Nrf2 leads to a coordinated
antioxidant and anti-inflammatory responses of the enzyme.
The structure of KEAP-1 is divided into four discrete domains:
the N-terminal broad complex, Tramtrack and Bric-a-̀Brac
(BTB) domain, a BACK domain, and a C-terminal Kelch
domain.27 The Kelch domain of the protein, showcasing a six-
bladed propeller-like structure, is required for substrate capture
and can be the structural motifs of Nrf2.28 We investigated the
binding properties of the secondary metabolites to the Nrf2-
binding region of the C-terminal Kelch domain of KEAP-1.
Dichamanetin (16) and cyathostemmine (13) conferred
Table 2. BE Values of 1−18 against PDE4 B2B, USP14, KEAP-1, and AChE
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.1c00137
ACS Omega 2021, 6, 8403−8417
8406
Figure 3. Docked poses of (a) bractelactone (14) against PDE4 B2 (PDB ID:1RO6); (b) dichamanetin (16) against USP14 (PDB ID: 6IIM); (c)
dichamanetin (16) against the KEAP-1 Kelch domain (PDB ID: 47LB); (d) grandifloracin (15) against the KEAP-1 BTB domain (PDB ID:
5DAD); and (e) 3-(3,4-dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-dimethoxychalcone (8) against AChE (PDB ID: 4EY6).
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strong binding affinities to the said binding region of the
protein with BEs of −11.1 and −10.6 kcal/mol, respectively
(Table 2, Figure 3). Dichamanetin’s (16) attachment to the
Kelch domain’s active site is primarily through H-bonding with
the ketone moiety of the chromanone core against Arg415 and
the hydroxyl of two benzyl substituents against Asn414 and
Ile416. A distinct pi−sigma interaction between the
chromanone core and Ala556 was also observed along with
stacked pi−pi attraction between the phenyl substituent and
Tyr572. With cyathostemmine (13), the complex was
stabilized through polar pi affinities with the tyrosines of the
Nrf2-binding region of the domain, specifically between (a)
the xanthene core and Tyr 334 and (b) the two benzoyl groups
against Tyr525 and Tyr572. In addition, 13 is further
strengthened through H-bonding of two ester groups against
Arg415 and Ser602.
The central BTB domain is another important region of
KEAP-1, particularly for its role in providing sensing
mechanisms to oxidative stress. This domain houses the
nucleophilic residue, Cys151, which was found to be one of the
most reactive residues in the regulation of cellular stress.29,30
This residue is a vital component for the post-translational
modification of KEAP-1 particularly upon exposure to
oxidative stress.31 Thus, the docking behavior of the secondary
metabolites was tested against the BTB domain of the enzyme,
particularly directed in and around Cys151. Interestingly,
grandifloracin (15) exhibited the highest affinity in the binding
region (BE = −7.3 kcal/mol) (Table 2, Figure 3). Compound
15 interacted with Cys151 through its tricyclododecenone core
and one of the benzoyl substituents via pi−alkyl interplay.
Several notable interactions include H-bonding and pi−cation
with Lys131, pi−sigma with His154, pi−pi stacking with
His129, and alkyl interactions with Ala88, Pro89, and Pro130.
Two other compounds showed significant binding to the BTB
active region, namely, valderramenol A (7) and 3-(3,4-
dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-dimethoxychalcone
(8), both with a BE of −7.1 kcal/mol. With compound 7,
Cys151 interacted via pi−alkyl with the compound’s core and
caused a steric bump with a hydroxy substituent. Several
stabilizing intermolecular forces were also observed such as
pi−cation with Lys131, pi stacking with His129, H-bonding
with His154, and pi−alkyl interactions with Ala88 and Arg135.
Meanwhile, compound 8 is hooked to the Cys151 residue
through pi−sulfur and pi−alkyl interactions with the B ring of
the chalcone core and the phenol substituent, respectively. H-
bonding with His154, pi−pi stacking with Tyr85, and pi−alkyl
interaction with Arg135 were observed between the compound
and the active surface of the BTB domain. All three top-scoring
metabolites interacting with the KEAP-1 BTB domain active
surface, centered around the nucleophilic Cys151, were enone-
bearing Michael acceptors. Thus, we speculate that a possible
Michael addition may occur, aside from conventional
intermolecular forces of attraction, between the electrophilic
metabolites and the nucleophilic Cys151 residue.
2.5. Frontier Molecular Orbital Energy Calculation of
Electrophilic U. albaMetabolites. The nucleophilic Cys151
residue of the BTB domain of KEAP-1 is considered as the
main cysteine sensor for the enone-bearing class of electro-
philic inducers which upregulate cytoprotective responses and
inhibit pro-inflammatory pathways of the enzyme. This
nucleophilic residue is structurally positioned at the surface
and not on a deep pocket, making it available for covalent
bond formation with incoming electrophiles, aside from the
usual intermolecular interactions predicted by molecular
docking. Frontier orbitals HOMO and LUMO were used to
calculate for the electrophilic potentials of the Michael
acceptor enone-bearing secondary metabolites of U. alba.
Parr and co-workers introduced the concept of the global
electrophilicity index based on a compound’s chemical
potential and hardness, which are functions of the energetics
of the molecular orbitals.32 The HOMO−LUMO energies,
hardness, chemical potential, and electrophilicity index are
presented in Table S7 and Figure 4. The parameters were
obtained by optimizing the target nucleophiles using B3LYP
calculation via DFT. In the present study, 7-benzoyloxy-2H-1-
benzopyran-2-one (1), grandifloracin (15), and valderramenol
A (7) showed the highest electrophilicity indices among the
metabolites. Of the three, however, grandifloracin (15)
conferred the highest HOMO−LUMO band gap, which
suggests the kinetic stability of the compound.33
Based on molecular docking analysis, which is grounded on
intermolecular forces, against the BTB domain of KEAP-1,
grandifloracin (15) and valderammenol A (7) were the top
binding ligands. Thus, we further investigated the potentiality
of a Michael addition reaction between these electrophilic
metabolites and the nucleophilic Cys151 residue of the
enzyme.
Figure 4. Frontier molecular orbitals of the grandifloracin (LUMO) and active nucleophilic residue of KEAP-1 (HOMO) calculated at the B3LYP/
STO-3G level of theory.
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2.6. Reaction Thermochemistry on the Michael
Addition of Grandifloracin (15) to Cys151 of the
KEAP-1 BTB Domain. α,β-Unsaturated carbonyl compounds
have received interest as drug candidates because of their
ability to interact with heteroatomic nucleophiles of enzymes,
such as the thiol group of cysteine residues, potentially through
Michael addition.34 We explored the possibility of a covalent
interaction between the electrophilic U. alba metabolites with
known anti-proliferative activity and the reactive cysteine
residues of KEAP-1. Among the main considerations for
exploiting the Michael acceptor reactivity is the presence of a
highly reactive, easy-to-access thiol group, particularly the
Cys151 found on the surface of the BTB domain of KEAP-1.
Grandilfloracin (15) was used as a Michael acceptor to
model the Michael addition to Cys151 of KEAP-1, represented
as a truncated tripeptide (Lys150-Cys151-Val152, 19). The
ground-state geometries of 15 and 19 were carried out using
DFT at the 6-31G**(d,p) level of theory in an aqueous
medium (polarizable continuum model, PCM, the solvent is
water) to mimic biological conditions. Ground-state geo-
metries are characterized though frequency calculation as those
obtaining real frequencies only. The proposed mechanism
involved the formation of an enol intermediate (20) through
concerted addition of a thiol group to the β-carbon of 15 and a
proton transfer to carbonyl oxygen, followed by a keto−enol
tautomerization to yield the final Cys151-grandifloracin keto
adduct (21) (Scheme 1).
Transition state (TS) geometries were predicted using the
QST3 method guided by the optimized geometries of two
minima: the reactants and the intermediate/product. The TS
was confirmed as having one, and only one, imaginary
frequency (a negative vibrational eigenvalue) corresponding
to the vibration along the reaction coordinate connecting the
two minima. The geometry of the first TS was searched by
positioning the thiol group (S32) of Cys151 close to the β-
carbon (C31) of grandifloracin with an initial distance rS···C =
Scheme 1. Proposed Michael Addition of Grandifloracin (15) to the Cys151 Tripeptide Segment (19) of the BTB Domain of
KEAP-1
Figure 5. DFT/6-31G**(d,p) reaction profile of the Michael addition of grandifloracin (15) and Cys151 tripeptide (19) (KEAP-1 BTB domain).
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.1c00137
ACS Omega 2021, 6, 8403−8417
8409
2.50 Å (Figure S4). The energy of activation of the reaction is
defined as the energy difference, ΔE⧧, of the first TS
grandifloracin-Cys151 adduct E⧧ and the ground-state Eo of
the reactants. This TS proceeds toward the formation of the
intermediate. The formation of intermediate is rate-determin-
ing (ΔE⧧ = 30.77 kcal/mol). Unlike most conjugate addition
reactions, this step is endothermic probably due to steric
interactions of the bulky grandifloracin structure 19 with
tripeptide 20, which means that steric accessibility of the
reactant could be a major driving force for the feasibility of the
reaction. A similar finding was also observed in the Michael
addition of deoxyguanosine to catechol estrogen-3,4-quinone35
and the aza-Michael addition of Lys16 (of β-amyloid Aβ42
fibrils) to oxidized (+)-taxifolin36 where in the formation of the
enol adduct is endothermic. The final step of the mechanism is
keto−enol tautomerization, with ΔEketo−enol⧧ = −20.02 kcal/
mol. As expected, the keto form of the adduct (product) is
more thermodynamically stable than the enol adduct
(intermediate). The reaction path and energetics of the
Michael addition reaction between grandifloracin and the
Cys151-containing tripeptide of the BTB domain of KEAP-1
are shown in Figure 5 and Table S8.
2.7. Molecular Docking to AChE. The secondary
metabolites from the UaD sub-extract of U. alba were also
tested for in silico binding toward AChE, of which, 3-(3,4-
dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-dimethoxychalcone
(8) had a BE of −9.8 kcal/mol (Table 2, Figure 3). The
chalcone core of 8 is bound to the binding site via hydrogen
bonding formed between Ser293 and Arg296 and the two
hydroxyl substituents, pi interactions with Tyr124 and Trp286
and a pi−lone pair attraction with Tyr337. Bractelactone (14)
also exhibited significant binding affinity with AChE (BE =
−9.8 kcal/mol). Post-docking analysis revealed that compound
14 is completely nestled onto the AChE’s active site gorge with
which the enzyme−ligand complex is stabilized mostly by pi−
pi stacking interplay with aromatic components of the
structure against Trp86, Tyr124, Trp286, and His447.
2.8. MD Simulation and Binding Free Energy
Calculations of Top-Ranked Ligands in Complex with
Target Enzymes. The dynamics of the five ligand bound
systemsbractelactone (14)-PDE4 B2B, 3-(3,4-dihydroxy-
benzyl)-3′,4′,6- trihydroxy-2,4-dimethoxychalcone (8)-AChE,
grandifloracin (15)-KEAP-1 (BTB domain), dichamanetin
(16)-KEAP-1 (Kelch domain), and dichamanetin (16)-
USP14were found to be stable during the course of the
MD simulation at 50 ns (Figure 6). In the case of bractelactone
(14)-PDE4 B2B, a minute fluctuation between 20 and 30 ns
was noted. The system, however, remained stable for the rest
of the time with an average root mean square deviation (rmsd)
of 2.5 Å. In addition, the stability of 3-(3,4-dihydroxy benzyl)-
3′,4′,6-trihydroxy-2,4-dimethoxychalcone (8) bound to AChE
was also measured. The system was noted to be stable with an
average rmsd of 1.5 Å. For this complex, an initial incremental
increase in the rmsd of the ligand bound system was observed
up to 10 ns, while for the rest of the simulation time, the
system attained stability. In the case of dichamanetin (16)-
KEAP-1 (Kelch domain), the system was found to be stable
with a little convergence at 42 ns. Meanwhile, grandifloracin
Figure 6. rmsd (Å) of top-scoring protein−ligand complexes as determined during 50 ns of MD simulation. The y-axis shows the rmsd value in Å
while the x-axis shows the time in nanoseconds.
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(15) in complex with the BTB domain of KEAP-1 was noted
to be stable throughout the simulation time with little
convergence at 30 ns. Lastly, dichamanetin (16) in complex
with USP 14 showed convergence at 10−15 ns, while for the
rest of the simulation time, the system attained stability.
The residual flexibility of each system was also determined
(Figure S8). As shown, the average root mean square
fluctuation (RMSF) of bractelactone (14) bound to PDE4
B2B was reported to be between 2.0 and 2.5 Å. On the other
hand, the average RMSF of 3-(3,4-dihydroxybenzyl)-3′,4′,6-
trihydroxy-2,4-dimethoxychalcone (8) bound to AChE was
observed to be 1−2.5 Å. A significant peak was also noted
between 195 and 200 residues in the said complex. For the
dichamanetin (16)-KEAP-1 (Kelch domain) complex, a higher
fluctuation between 52 and 60 residues was noted, whereas
grandifloracin (15) in complex with the BTB domain of
KEAP-1 showed a much higher fluctuation. The dichamanetin
(16)−USP14 complex possessed an even higher fluctuation in
the regions of 40−50, 120−130, 180−200, 220−230, and
255−260.
The bractelactone (14)-PDE4 B2B exhibited a degree of
compactness up to 30 ns with an average Rg value of 20.8 Å.
Meanwhile, 3-(3,4-dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-di-
methoxychalcone (8) bound to AChE had an average Rg of
21.0 Å. Subsequently, the binding of grandifloracin (15) and
dichamanetin (16) to the different binding domains of KEAP-
1 showed stable but different Rg patterns. The average Rg value
for the dichamanetin (16)−KEAP-1 (Kelch) complex was
reported to be 14 Å, while for grandifloracin (15) the Rg value
was observed to be 18 Å. The higher Rg value for grandifloracin
might be due to the higher fluctuation pattern observed in the
RMSF of the grandifloracin (15)-KEAP-1 (BTB domain)
system. In the case of the dichamanetin (16)−USP14 complex,
the average Rg value was observed to be 21.0 Å. Overall, the
ligand-bound systems possessed structural compactness
favoring the tight binding of these ligands to their respective
receptors (Figure S9).
The trajectories from MD simulations were subjected to
total binding free energy calculations. The BE for bractelactone
(14)-PDE4 B2B was reported to be −66.64 kcal/mol.
Furthermore, a relatively higher energy binding was detected
for 3-(3,4-dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-dimethoxy-
chalcone (8) bound to the AChE receptor. The BE for this
complex was at −77.46 kcal/mol, suggesting the strong
inhibitory property of this compound to the AChE receptor.
Meanwhile, for KEAP-1, two of its binding domains were
targeted. Dichamanetin (16) bound to the Kelch domain was
found to have a BE of −55.76 kcal/mol, whereas grandifloracin
(15) targeting the BTB domain was reported to have a total
BE of −48.41 kcal/mol. On the other hand, dichamanetin (16)
bound to USP14 possessed a very strong BE. The total BE for
this system was observed to be −83.98 kcal/mol. The other
energy terms such as vdW, electrostatic forces, polar solvation,
and solvent-accessible surface area for each system that
contributed to the total BE are given in Table S15.
2.8.1. Hydrogen Bonding Analysis. In order to determine
the half-life of each interaction with the key residues, we used
the hydrogen bonding occupancy approach. A 50-ns trajectory
was used for each system to monitor the hydrogen bonding
during the course of simulation. It can be seen that most of the
ligands formed significant hydrogen bonds for a longer time. In
case of bractelactone_PDE4B2B, Tyr233, His238, His274,
Figure 7. Hydrogen bonding occupancy of the key residues during the course of simulation. Each residue bonding is given in percentage
trajectories.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.1c00137
ACS Omega 2021, 6, 8403−8417
8411
Asn283, and Met347 were actively involved in hydrogen
bonding. It can be seen that Tyr233 was involved in 89% of the
MD trajectories. In dimethoxychalcone_AChE residues Asp74,
Tyr124, Glu202, Ser293, and Arg296 were involved among
which the life time of Ser293 was reported to be 92%.
Furthermore, residues Ser363, Asn414, Arg415, and Tyr436 in
dichamanetin_KEAP1-Kelch were actively involved in hydro-
gen bonding. The grandifloracin_KEAP1-BTB complex was
reported to be involved in interactions with Ala88, His129,
Pro130, Lys131, and Arg135. Only three residues Arg415,
Ile416, and His426 were reported in the dichamanetin_USP14
complex. All the results are calculated in percentage trajectories
(0.89 mean 89% of the trajectories) and given in Table S17.
The intra-molecule H-bonds are given in Figure 7.
2.9. Drug-likeness and ADMET Prediction of Secon-
dary Metabolites from UaD. The overall pharmacokinetic
behavior of 1−18 was determined through in silico absorption,
distribution, metabolism, and excretion (ADME) screening.
Based on Lipinski’s rule of five, the druggability of the
compounds was predicted using the following descriptors:
molecular weight, lipophilicity (reported as octanol−water
partition coefficient), and the number of hydrogen bond
donors and acceptors. Interestingly, all of the 18 secondary
metabolitesincluding the top-ranked compounds such as 3-
(3,4-dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-dimethoxychal-
cone (8), cyathostemmine (13), bractelactone (14), grandi-
floracin (15) and dichamanetin (16)exhibited good
bioavailability and drug-likeness by fulfilling Lipinski’s criteria
(Table S18). Furthermore, the BOILED-Egg (brain or
intestinal estimated permeation predictive model), an intuitive
graphical plot of the functions of lipophilicity and apparent
polarity, was used to predict passive intestinal absorption and
brain permeation of the compounds (Figure 8). Compounds
located in the yellow region (yolk) have a high probability of
blood−brain barrier (BBB) penetration while those in the
white region have the propensity for passive absorption
through the gastrointestinal (GI) tract. Dichamanetin (16),
which demonstrated strong binding affinity to the target
enzymes PDE4 B2B, USP14, and KEAP-1 (Kelch domain),
was predicted to have good GI absorption and poor BBB
crossing capacities. Similarly, grandifloracin (15), which
showed favorable binding to KEAP-1 (BTB domain), shared
the same pattern of bioavailability as dichamanetin (16).
Despite having good binding affinity to AChE, compound 8
was predicted to be poorly absorbed in the GI tract, hence
explaining its location outside the white portion of the
BOILED-Egg model. A prediction of the toxicities, such as
mutagenicity, tumorigenicity, irritant effect, and reproductive
toxicity, of the 18 secondary metabolites from U. alba was also
performed using OSIRIS Property Explorer (Table S19).
Among the top-ranked compounds, 3-(3,4-dihydroxybenzyl)-
3′,4′,6-trihydroxy-2,4-dimethoxychalcone (8) did not demon-
strate any form of toxicity. Grandifloracin (15), however,
demonstrated an irritant effect, whereas dichamanetin (16)
was predicted to confer tumorigenicity. Both compounds 15
and 16 were projected to induce reproductive toxicity. Thus,
iteration of their structures is highly encouraged to improve
their toxicity profile.
3. CONCLUSIONS
The DCM sub-extract of U. alba (UaD) showed anti-
phosphodiesterase and consequently antiproliferative and
anti-cholinesterase properties in vitro. Eighteen putative
secondary compounds were detected and in silico target fishing
identified dichamenetin (16) with strong binding affinities to
PDE4 B2B, USP14, and the KEAP-1 Kelch domain. On the
other hand, 3-(3,4-dihydroxybenzyl)-3′,4′,6-trihydroxy-2,4-di-
Figure 8. Prediction of GI tract and brain permeation of the top-ranked U. alba secondary metabolites3-3,4-dihydroxybenzyl)-3′,4′,6-trihydroxy-
2,4-dimethoxychal cone (8), cyathostemmine (13), bractelactone (14), grandifloracin (15), and dichamanetin (16)by brain or the intestinal
estimated permeation predictive model (BOILED-Egg) method.
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methoxychalcone (8) and grandifloracin (15) demonstrated
favorable binding to AChE and the KEAP-1 BTB domain,
respectively. We also demonstrated the potential of the most
electrophilic grandifloracin (15) to initiate a Michael addition
reaction with the active nucleophilic Cys151-containing
tripeptide in the KEAP-1 BTB domain. MD simulation
revealed the complexes formed between the top-ranked ligands
and their protein targets to be thermodynamically stable. With
favorable pharmacokinetic properties of top-ranked ligands,
these results warrant further investigations on the secondary
metabolites of U. alba against their respective target proteins
for the discovery of new drug leads against cancer and AD.
4. MATERIALS AND METHODS
4.1. Collection and Identification of Plant Material.
The leaves of U. alba were collected in the lowlands of Palauig,
Zambales, Luzon, Philippines (15°43′ N, 119°91′ E) in
October 2013. These were authenticated with voucher
specimens (USTH 1631) deposited at the University of
Santo Tomas Herbarium and at the Philippine National
Herbarium, Manila, Philippines.
4.2. Crude Extraction and Fractionation. The ground
air-dried leaves (2.1 kg) were extracted with technical-grade
(1:1) DCM−MeOH and concentrated in vacuo at 45 °C. 349 g
of crude DCM−MeOH extract (Ua) was yielded. Ua crude
extract was suspended in distilled water and partitioned
according to increasing polarity, yielding three sub-extracts,
namely, petroleum ether (UaP), DCM (UaD), and n-butanol
(UaB) sub-extracts. The sub-extracts were concentrated in
vacuo and tested for biological activities.
4.3. Phosphodiesterase (PDE4 B2) Inhibition Assay.
The effect of U. alba DCM sub-extract on human recombinant
cAMP-specific phosphodiesterase (PDE4 B2) was studied with
the diluted test sample in 20 μL of 50 mM Tris-HCl buffer
(pH 7.5) containing 8.3 mM MgCl2, 1.7 mM EGTA, and 5 U
recombinant human cAMP-specific PDE4 B2 (Biocat 60042-
BPS, Heidelberg, Germany). The reaction was started with 20
μL of 24 μM cAMP (Sigma A9501, Taufkirchen, Germany)
dissolved in 50 mM Tris-HCl buffer (pH 7.5) containing 8.3
mM MgCl2 and 1.7 mM EDTA. After an incubation period of
30 min at 30 °C, the reaction was stopped and the AMP
concentration was quantified with the PDELight HTS cAMP
Phosphodiesterase Assay Kit (Lonza, LT07-600, Koeln,
Germany) following the manufacturer’s instructions. The
luminescence was measured using the microtiter plate reader
Infinite M200 (TECAN) with 0.1 s integration time. Rolipram
was used as the reference PDE inhibitor drug. IC50 value is
defined as the concentration of the plant material required to
inhibit PDE4 B2 activity by 50%.37
4.4. Antiproliferative and Cytotoxicity Assay. The
antiproliferative and cytotoxic properties of the plant samples
were assessed using CellTiter-Blue assay as previously
described.17,21,38 The antiproliferation assay was carried out
by testing the test substance dissolved in DMSO against
chronic myelogenous leukemia (K-562, DSM ACC 10) and
human umbilical vein endothelial cells (HUVEC, CRL-1730).
Meanwhile, cytotoxicity assessment was carried out on the
subconfluent monolayers of human cervical cancer cells
(HeLa, DSM ACC 57). Optical densities were measured at
660 nm in SUNRISE microplate reader (TECAN, Crailsheim,
Germany). The GI50 and CC50 values were defined as being
where the dose response curve intersected the 50% line
compared to untreated control. These values were determined
using the software Magellan (TECAN). Doxorubicin was used
as the reference drug. The selectivity index was computed for
those samples with antiproliferative property using the
formula: GI50 HUVEC/GI50 K-562.
17,38
4.5. AChE Inhibition Assay. The AChE inhibitory
property was evaluated using slightly modified Ellman’s
assay.39 Electric eel AChE (type-VI-S, EC 3.1.1.7, Sigma)
was used as the enzyme source, while acetylthiocholine iodide
(ATCI, Sigma, St. Louis, MO, USA) was used as the substrate
of the reaction. 5,5-Dithiobis-(2-nitrobenzoic acid) (Sigma, St.
Louis, MO, USA) was used for the measurement of the
cholinesterase activity. Test samples were reconstituted with
50% DMSO. About 140 μL of 0.1 mM sodium phosphate
buffer (pH 8.0), 20 μL of 3 mM DTNB, and 20 μL of 0.36 U/
mL of AChE were added in the reaction, followed by
incubation for 15 min at 37 °C and addition of 10 μL of 15
mM ATCI. The microplates were then read at 412 nm using a
Glomax microplate reader (Promega, Madison, Wisconsin).
Galantamine was used as the reference drug. The IC50 value is
defined as the concentration of the plant material required to
inhibit AChE activity by 50%.
4.6. LCHigh-Resolution MS Analysis. The U. alba
DCM sub-extract (UaD), being the most biologically active,
was chemically profiled for the identification of its putative
secondary metabolites using LC-HR-ESIMS-QToF performed
on a Shimadzu LC-20 AD apparatus equipped with an
autosampler (SIL-20A, Shimadzu), diode array detector (SPD-
M20AV, Shimadzu), and coupled with a microToF II (Bruker
Daltonics) ESI-QToF mass spectrometer. HPLC column
Chromolith Performance RP-18e (2.0 × 100 mm i.d.) was
used for the analysis. The eluents were acetonitrile and water
with 0.1% acetic acid. After injecting 5 μL of the UaD sub-
extract, flow elution was set at 0.2 mL/min. The effluents were
monitored at 350 nm. The mass spectra were recorded in the
mass range m/z 50 to 2000. The Bruker DataAnalysis 4.3
software (Bruker, Germany) was used for data acquisition and
analysis. Individual components were identified by comparison
of their m/z values in the total ion count profile with those
compounds described in literature or by matching their MS/
MS spectra with those reported in a public repository of mass
spectral data called MassBank.40
4.7. Molecular Docking. The binding affinities of the
ligands from UaD to the docking sites of PDE4 B2B (PDB ID:
1RO6), AChE (PDB ID:4EY6), USP14 (PDB ID:6IIM), the
KEAP1-Kelch domain (PDB ID: 4L7B), and the KEAP1-BTB
domain (PDB ID:5DAD) were calculated (Figure S10).
Molecular docking experiments were performed on the
UCSF Chimera platform.41 The three-dimensional structures
of the protein were added to the docking platform as PDB
formats. Each protein crystal structure was processed by
removing existing co-crystallized ligands and water molecules.
Meanwhile, the ligands were added to the docking platform,
rendered from SMILES notation or added as a SYBYL mol2
file. Minimization and dock-prepping of ligand and protein
structures were done by adding the missing hydrogen atoms
and appropriate charges to the structures employing the
Gasteiger charge method computed using Amber’s Ante-
chamber module.42 The docking procedure was done using a
flexible ligand into a flexible active site protocol, where the
ligand was allowed to be flexible and torsion within a grid box
encompassing the ligand-binding cavity of each enzyme. A grid
box was set around the bound co-crystallized ligand of the
enzyme. The coordinates of the grid box, with the size 25 × 25
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× 25 points, is summarized in Table S20. With all docking
parameters maintained at default values, (number of binding
modes = 10 at maximum exhaustiveness search), molecular
docking simulation was performed following the Broyden−
Fletcher−Goldfarb−Shanoo algorithm of AutoDock Vina
(version 1.1.2).43 After each run, AutoDock Vina provides a
set of docking poses for each ligand with calculated binding
affinities in which the docking pose with the best affinity was
chosen to represent the set. This was then subjected to post-
dock analysis. Visualization and analysis of the enzyme−ligand
complex conformation were carried out using Biovia Discovery
Studios (version 4.1) and LigPlot+ (version 2.2). Validation of
the docking protocol was done by extracting the bound co-
crystallized ligand and re-docking it to the set grid. rmsd
between the co-crystal and the re-docked pose was obtained.
The rmsd’s in all the protein complexes were found to be less
than 2 Å (ranging from 0.157 to 1.511 Å, Table S21), which
indicates that the computed ligand−protein conformation is
good.44
4.8. Reaction Thermochemistry and Frontier Molec-
ular Orbital Energy Calculation. All calculations were
performed within the Gaussian16W suite of programs.45 Initial
conformational searches of all species were performed by
scanning all freely rotating dihedral angles at the Hartree−Fock
level of theory and the 6-31G** basis set to locate their
approximate global energy minimum structures prior to full
geometry optimization. Frontier molecular orbital energies
(HOMO, EHOMO and LUMO, ELUMO) of the electrophilic U.
alba metabolites, the Michael acceptors, were calculated for
their empirical global electrophilicity index (ω)32,46
ω μ η= /22
where μ is the chemical potential or the first derivative of total
energy, E, with respect to the electron number, N, and η is the
hardness or the second derivative of total energy with respect


































Geometry optimization and energy calculation of the stable
species of the proposed Michael addition mechanism were
performed via DFT B3LYP/6-31G**(d,p).47 Approximate
locations of TSs were determined by performing relaxed
potential energy surface scans as well as refinement of the TS
structure using TS Berney and QST3 optimization at the same
level of theory. The TS was confirmed by intrinsic reaction
coordinate calculations and were distinguished as having a
single imaginary vibrational frequency. All potential energy
surface scans, geometry optimizations, and single-point
calculations were performed at 298.15 K, 1.0 atm pressure,
and in a PCM solvent for water.
4.9. MD Simulation and Binding Free Energy
Calculation. The MD behavior of the top scoring complexes
was simulated using Amber 18.30 Drug topologies were
generated using antechamber.48 With TIP3P water box and
Na+ ions, the systems were solvated and neutralized. Gentle
energy minimization in two steps was performed to relax all the
systems followed by heating. The steepest descent algorithm
(42) and the conjugate gradient algorithm was used for 6000
and 3000 cycles, respectively (43). The particle mesh Ewald
algorithm for short- and long-range interactions was also used
with a cutoff distance of 10.0 Å. The system was heated up to
300 K with ntlism 10,000, ntx was set as 1 while ntb was used
as 0. Finally, a total of 50 ns simulations for each system were
performed.49 The detailed information on the parameters used
in this study for MD simulation are given in supplementary file
Table S16. CPPTRAJ and PTRAJ were used to evaluate the
trajectories for stability (rmsd) and residual flexibility
(RMSF).50
Trajectories from MD simulations were subjected to binding
free energy calculations using the MMPBSA.py script.51 This
method is widely implemented by different studies to calculate
the BE of a ligand−protein, protein−protein, and protein−
nucleic acid complexes.52−54 The total BE (ΔG) was then
calculated using the equation
Δ = Δ − [Δ + Δ ]G G G Gbind complex receptor ligand
To further understand each energy term such as electrostatic
energy, van der Waals forces, polar and nonpolar interactions,
which may contribute to the total energy (G), the equation
below was used
= + + + +G G G G G Gbond ele vdW pol npol
Furthermore, hydrogen bonding analysis of each protein−
ligand complex was performed to reveal the half-life of each
interaction during MD simulation.
4.10. ADMET Profiling. Computational prediction of the
ADME properties of secondary metabolites from UaD was
carried out using SwissADME software (Molecular Modeling
Group, Swiss Institute of Bioinformatics, 2019). Pharmacoki-
netic profiles were evaluated according to Lipinski’s “rule-of-
five”, which analyzes the biochemical features of a drug that
may influence its absorption and permeation across cell
membranes. For a compound to exhibit drug likeness, at least
three of the following Lipinski’s criteria must be fulfilled:
molecular weight < 500 Da, calculated lipophilicity (log P) < 5,
number of hydrogen-bond acceptors <10, and number of
hydrogen-bond donors <5. Furthermore, OSIRIS property
explorer program (Thomas Sander, Idorsia Pharmaceuticals
Ltd., 2017) was employed for in silico toxicity prediction, which
takes into account the potential mutagenicity, tumorigenicity,
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